UOC
CNCE

UBS O'Connor’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

UBS O'Connor’s Portfolio CNCE Stock Details CNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-50,000
Closed -$757K – 921
2015
Q1 		$757K Buy
+50,000
New +$698K 0.02% 443

Other funds holding CNCE

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
SAM
Senzar Asset Management New York $34.7M AUM 0.56% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return

UBS O'Connor's CNCE Position: Q2 2015 in Review

UBS O'Connor sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q2 2015, closing a stake of 50,000 shares — an estimated $757K sold.

UBS O'Connor first reported a position in CNCE in Q1 2015 and held it in 1 quarter. The position peaked at $757K in Q1 2015. 67 funds tracked by Wall St. Rank hold CNCE as of Q2 2015.

  • UBS O'Connor reported no remaining Concert Pharmaceuticals, Inc. position as of Q2 2015 after selling out during the quarter.
  • UBS O'Connor sold 50,000 Concert Pharmaceuticals, Inc. shares in Q2 2015, an estimated $757K.
  • UBS O'Connor first reported a position in Concert Pharmaceuticals, Inc. in Q1 2015 and held it in 1 quarter.
  • UBS O'Connor's Concert Pharmaceuticals, Inc. position peaked at $757K in Q1 2015.
  • 67 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q2 2015.

Based on UBS O'Connor's 13F filing for Q2 2015, filed 13 Aug 2015.